Efficacy, Safety and the Lymphocyte Subset Changes of Low-Dose IL-2 in Patients with Autoimmune Rheumatic Diseases: A Systematic Review and Meta-Analysis

[1]  Yan Liu,et al.  Low-dose Interleukin-2 For Psoriasis Therapy Based on the Regulation of Th17/Treg Cell Balance in Peripheral Blood , 2023, Inflammation.

[2]  M. Miao,et al.  Low-dose IL-2 mitigates glucocorticoid-induced Treg impairment and promotes improvement of SLE , 2023, Signal Transduction and Targeted Therapy.

[3]  Xiao-feng Li,et al.  Low-dose IL-2 improved clinical symptoms by restoring reduced regulatory T cells in patients with refractory rheumatoid arthritis: A randomized controlled trial , 2022, Frontiers in Immunology.

[4]  Xiaofeng Li,et al.  Low-dose IL-2 therapy restores imbalance between Th17 and regulatory T cells in patients with the dermatomyositis combined with EBV/CMV viraemia. , 2022, Autoimmunity reviews.

[5]  D. Klatzmann,et al.  Low-dose interleukin-2 therapy in active systemic lupus erythematosus (LUPIL-2): a multicentre, double-blind, randomised and placebo-controlled phase II trial , 2022, Annals of the Rheumatic Diseases.

[6]  T. Ding,et al.  Absolute decrease in regulatory T cells and low‐dose interleukin‐2 therapy: restoring and expanding regulatory T cells to treat systemic sclerosis: a 24‐week study , 2022, Clinical and experimental dermatology.

[7]  Xiaofeng Li,et al.  Short-term and low-dose IL-2 therapy increases the reduced Treg cells in patients with microscopic polyangiitis. , 2022, Autoimmunity reviews.

[8]  G. Tsokos,et al.  Therapeutic potential of interleukin-2 in autoimmune diseases. , 2022, Trends in molecular medicine.

[9]  T. Rauen,et al.  T cell dysregulation in SLE. , 2022, Clinical immunology.

[10]  Xiaofeng Li,et al.  Low-dose IL-2 therapy limits the reduction in absolute numbers of peripheral lymphocytes in systemic lupus erythematosus patients with infection , 2022, Current medical research and opinion.

[11]  Y. Zhufeng,et al.  Modification of Intestinal Microbiota Dysbiosis by Low-Dose Interleukin-2 in Dermatomyositis: A Post Hoc Analysis From a Clinical Trial Study , 2022, Frontiers in Cellular and Infection Microbiology.

[12]  S. Ghosh,et al.  Intranuclear Delivery of HIF-1α-TMD Alleviates EAE via Functional Conversion of TH17 Cells , 2021, Frontiers in Immunology.

[13]  M. Miao,et al.  Treatment of Active Idiopathic Inflammatory Myopathies by Low-Dose Interleukin-2: A Prospective Cohort Pilot Study , 2021, Rheumatology and Therapy.

[14]  G. Riemekasten,et al.  Low-Dose IL-2 Therapy in Autoimmune and Rheumatic Diseases , 2021, Frontiers in Immunology.

[15]  Xiaofeng Li,et al.  Low-dose Interleukin-2: Biology and therapeutic prospects in rheumatoid arthritis. , 2020, Autoimmunity reviews.

[16]  Jing Luo,et al.  Low-dose IL-2 effectively restored decreased regulatory T cells in patients with Behçet's disease. , 2020, Clinical and experimental rheumatology.

[17]  Lei Jiang,et al.  SAT0278 LOW-DOSE IL-2 RESTORES TREG-MEDIATED IMMUNE TOLERANCE IN PATIENTS WITH ANCA-ASSOCIATED VASCULITIS , 2020 .

[18]  G. Tsokos.  Autoimmunity and organ damage in systemic lupus erythematosus , 2020, Nature Immunology.

[19]  Jing Luo,et al.  The numbers of peripheral regulatory T cells are reduced in patients with psoriatic arthritis and are restored by low-dose interleukin-2 , 2020, Therapeutic advances in chronic disease.

[20]  Jing Luo,et al.  Absolute reduction of regulatory T cells and regulatory effect of short-term and low-dose IL-2 in polymyositis or dermatomyositis. , 2019, International immunopharmacology.

[21]  G. Kroemer,et al.  Effects of interleukin-2 in immunostimulation and immunosuppression , 2019, The Journal of experimental medicine.

[22]  J. Alexander,et al.  Efficacy and safety of low-dose IL-2 in the treatment of systemic lupus erythematosus: a randomised, double-blind, placebo-controlled trial , 2019, Annals of the rheumatic diseases.

[23]  G. Collins,et al.  Global, regional and national burden of rheumatoid arthritis 1990–2017: a systematic analysis of the Global Burden of Disease study 2017 , 2019, Annals of the rheumatic diseases.

[24]  Liguang Sun,et al.  Low dose of IL-2 combined with rapamycin restores and maintains the long-term balance of Th17/Treg cells in refractory SLE patients , 2019, BMC Immunology.

[25]  Xia Zhang,et al.  Interleukin-2 Deficiency Associated with Renal Impairment in Systemic Lupus Erythematosus. , 2019, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[26]  Xia Zhang,et al.  Clinical Relevance of Autoantibodies against Interleukin-2 in Patients with Systemic Lupus Erythematosus , 2018, Chinese medical journal.

[27]  Jing Luo,et al.  Short-term and low-dose IL-2 therapy restores the Th17/Treg balance in the peripheral blood of patients with primary Sjögren’s syndrome , 2018, Annals of the rheumatic diseases.

[28]  W. Graninger,et al.  Therapeutic Potential of Targeting the Th17/Treg Axis in Autoimmune Disorders , 2017, Molecules.

[29]  Y. Kamatani,et al.  GWAS of clinically defined gout and subtypes identifies multiple susceptibility loci that include urate transporter genes , 2016, Annals of the rheumatic diseases.

[30]  E. Morand,et al.  Low-dose interleukin-2 treatment selectively modulates CD4+ T cell subsets in patients with systemic lupus erythematosus , 2016, Nature Medicine.

[31]  D. Klatzmann,et al.  The promise of low-dose interleukin-2 therapy for autoimmune and inflammatory diseases , 2015, Nature Reviews Immunology.

[32]  S. Dai,et al.  Prevalence of rheumatic diseases and disability in China , 2009, Rheumatology International.

[33]  C. Lau,et al.  Pathogenesis of systemic lupus erythematosus , 2003, Journal of clinical pathology.